<?xml version="1.0" encoding="UTF-8"?>
<html xmlns="http://www.w3.org/1999/xhtml">
 <head charset="UTF-8"/>
 <style> * { font-family : helvetica;} .font19 { font-size : 19; } .font20 { font-size : 20; } .font21 { font-size : 21; } .font24 { font-size : 24; } .font26 { font-size : 26; } .font10 { font-size : 10; } .font11 { font-size : 11; } .font12 { font-size : 12; } .font13 { font-size : 13; } .font30 { font-size : 30; } .font15 { font-size : 15; }</style>
 <body>
  <p>
   <span class="font30">and </span>
   <span class="font26">the </span>
   <span class="font24">with </span>
   <span class="font21">patients </span>
   <span class="font20">for </span>
   <span class="font19">COVID- </span>
   <span class="font15">treatment </span>
   <span class="font15">clinical </span>
   <span class="font13">coronavirus </span>
   <span class="font13">severe </span>
   <span class="font13">trial </span>
   <span class="font12">{background </span>
   <span class="font12">study </span>
   <span class="font12">viral </span>
   <span class="font12">[published </span>
   <span class="font12">respiratory </span>
   <span class="font12">that </span>
   <span class="font12">therapy </span>
   <span class="font12">HCQ </span>
   <span class="font12">The </span>
   <span class="font12">ahead </span>
   <span class="font12">are </span>
   <span class="font12">online </span>
   <span class="font12">print </span>
   <span class="font12">June </span>
   <span class="font12">have </span>
   <span class="font12">randomized </span>
   <span class="font12">receiving </span>
   <span class="font12">disease </span>
   <span class="font12">margin </span>
   <span class="font11">{border-style </span>
   <span class="font11">acute </span>
   <span class="font11">antiviral </span>
   <span class="font11">hydroxychloroquine </span>
   <span class="font11">plasma </span>
   <span class="font11">px;} </span>
   <span class="font11">retrospective </span>
   <span class="font11">#ffffff;} </span>
   <span class="font11">COVID-: </span>
   <span class="font11">Med </span>
   <span class="font11">RCT </span>
   <span class="font11">from </span>
   <span class="font11">improvement </span>
   <span class="font11">mortality </span>
   <span class="font11">novel </span>
   <span class="font11">syndrome </span>
   <span class="font11">was </span>
   <span class="font11">SARS-CoV- </span>
   <span class="font11">convalescent </span>
   <span class="font11">days </span>
   <span class="font11">hospitalized </span>
   <span class="font11">results </span>
   <span class="font11">safety </span>
   <span class="font11">Infect </span>
   <span class="font11">LPV/RTV </span>
   <span class="font11">but </span>
   <span class="font11">therapies </span>
   <span class="font11">COVID-. </span>
   <span class="font11">Clinical </span>
   <span class="font11">been </span>
   <span class="font11">inÂ </span>
   <span class="font11">open-label </span>
   <span class="font11">reported </span>
   <span class="font11">therapeutic </span>
   <span class="font11">tocilizumab </span>
   <span class="font11">care </span>
   <span class="font11">has </span>
   <span class="font11">trials </span>
   <span class="font11">use </span>
   <span class="font11">vitro </span>
   <span class="font11">compared </span>
   <span class="font11">controlled </span>
   <span class="font11">evidence </span>
   <span class="font11">remdesivir </span>
   <span class="font11">studies </span>
   <span class="font11">this </span>
   <span class="font11">within </span>
   <span class="font10">Global </span>
   <span class="font10">May </span>
   <span class="font10">analysis </span>
   <span class="font10">azithromycin </span>
   <span class="font10">chloroquine </span>
   <span class="font10">clearance </span>
   <span class="font10">data </span>
   <span class="font10">emerging </span>
   <span class="font10">infection </span>
   <span class="font10">review </span>
   <span class="font10">than </span>
   <span class="font10">time </span>
   <span class="font10">-patient </span>
   <span class="font10">CPT </span>
   <span class="font10">Dis </span>
   <span class="font10">Sci </span>
   <span class="font10">combination </span>
   <span class="font10">confidence </span>
   <span class="font10">efficacy </span>
   <span class="font10">interval, </span>
   <span class="font10">not </span>
   <span class="font10">other </span>
   <span class="font10">pneumonia </span>
   <span class="font10">their </span>
   <span class="font10">ventilation </span>
   <span class="font10">were </span>
   <span class="font10">â‰¥ </span>
   <span class="font10">(P=.) </span>
   <span class="font10">April </span>
   <span class="font10">China </span>
   <span class="font10">Engl </span>
   <span class="font10">Health </span>
   <span class="font10">Multi </span>
   <span class="font10">National </span>
   <span class="font10">None </span>
   <span class="font10">RNA </span>
   <span class="font10">Single </span>
   <span class="font10">after </span>
   <span class="font10">critically </span>
   <span class="font10">current </span>
   <span class="font10">found </span>
   <span class="font10">ill </span>
   <span class="font10">including </span>
   <span class="font10">its </span>
   <span class="font10">length </span>
   <span class="font10">may </span>
   <span class="font10">px; </span>
   <span class="font10">treated </span>
   <span class="font10">{font-family </span>
   <span class="font10">Case </span>
   <span class="font10">However, </span>
   <span class="font10">Phase </span>
   <span class="font10">Res </span>
   <span class="font10">United </span>
   <span class="font10">]medRxivhttps://doi.org/./... </span>
   <span class="font10">also </span>
   <span class="font10">benefit </span>
   <span class="font10">confirmed </span>
   <span class="font10">control </span>
   <span class="font10">font-size </span>
   <span class="font10">inhibition </span>
   <span class="font10">more </span>
   <span class="font10">pandemic </span>
   <span class="font10">ratio, </span>
   <span class="font10">standard </span>
   <span class="font10">these </span>
   <span class="font10">using </span>
   <span class="font10">-day </span>
   <span class="font10">Accessed </span>
   <span class="font10">Convalescent </span>
   <span class="font10">Organization </span>
   <span class="font10">Therapy </span>
   <span class="font10">Trial </span>
   <span class="font10">World </span>
   <span class="font10">Wuhan, </span>
   <span class="font10">activity </span>
   <span class="font10">available </span>
   <span class="font10">baricitinib </span>
   <span class="font10">being </span>
   <span class="font10">cases </span>
   <span class="font10">cytokine </span>
   <span class="font10">did </span>
   <span class="font10">double-blind, </span>
   <span class="font10">double; </span>
   <span class="font10">had </span>
   <span class="font10">health </span>
   <span class="font10">identifier: </span>
   <span class="font10">intensive </span>
   <span class="font10">load </span>
   <span class="font10">lopinavir/ritonavir </span>
   <span class="font10">multicenter </span>
   <span class="font10">multicenter, </span>
   <span class="font10">only </span>
   <span class="font10">oxygen </span>
   <span class="font10">plus </span>
   <span class="font10">provide </span>
   <span class="font10">rapid </span>
   <span class="font10">scale </span>
   <span class="font10">such </span>
   <span class="font10">therapeutics </span>
   <span class="font10">those </span>
   <span class="font10">through </span>
   <span class="font10">treatments </span>
   <span class="font10">trial: </span>
   <span class="font10">virus </span>
   <span class="font10">will </span>
   <span class="font10">(ClinicalTrials.gov </span>
   <span class="font10">(hazard </span>
   <span class="font10">Acad </span>
   <span class="font10">COVID-, </span>
   <span class="font10">East </span>
   <span class="font10">Elsevier </span>
   <span class="font10">Emerging </span>
   <span class="font10">Hydroxychloroquine </span>
   <span class="font10">ICU </span>
   <span class="font10">LPV/RTV, </span>
   <span class="font10">March </span>
   <span class="font10">Middle </span>
   <span class="font10">NCT) </span>
   <span class="font10">Preclinical: </span>
   <span class="font10">Remdesivir </span>
   <span class="font10">Study </span>
   <span class="font10">all </span>
   <span class="font10">arm </span>
   <span class="font10">basis </span>
   <span class="font10">between </span>
   <span class="font10">border-color </span>
   <span class="font10">border-width </span>
   <span class="font10">case </span>
   <span class="font10">characteristics </span>
   <span class="font10">comparing </span>
   <span class="font10">development </span>
   <span class="font10">difference </span>
   <span class="font10">diseases </span>
   <span class="font10">double-blind </span>
   <span class="font10">early </span>
   <span class="font10">effective </span>
   <span class="font10">efficacy. </span>
   <span class="font10">evolving </span>
   <span class="font10">first </span>
   <span class="font10">group </span>
   <span class="font10">hospital </span>
   <span class="font10">human </span>
   <span class="font10">inflammatory </span>
   <span class="font10">inhibitor </span>
   <span class="font10">interferon </span>
   <span class="font10">management </span>
   <span class="font10">mechanical </span>
   <span class="font10">ordinal </span>
   <span class="font10">outcomes </span>
   <span class="font10">potential </span>
   <span class="font10">preliminary </span>
   <span class="font10">promising </span>
   <span class="font10">randomized, </span>
   <span class="font10">reductions </span>
   <span class="font10">replication </span>
   <span class="font10">resulted </span>
   <span class="font10">scientific </span>
   <span class="font10">search </span>
   <span class="font10">series </span>
   <span class="font10">solid; </span>
   <span class="font10">treating </span>
   <span class="font10">used </span>
   <span class="font10">vaccines </span>
   <span class="font10">who </span>
   <span class="font10">{font-style </span>
   <span class="font10">{font-weight </span>
   <span class="font10">Agents </span>
   <span class="font10">Clin </span>
   <span class="font10">Cohort: </span>
   <span class="font10">Covid- </span>
   <span class="font10">Covid-NÂ </span>
   <span class="font10">Hospital </span>
   <span class="font10">III, </span>
   <span class="font10">IL- </span>
   <span class="font10">Janus </span>
   <span class="font10">Natl </span>
   <span class="font10">Placebo </span>
   <span class="font10">SARS, </span>
   <span class="font10">SARS-CoV-, </span>
   <span class="font10">SOLIDARITY </span>
   <span class="font10">SoC </span>
   <span class="font10">SoCÂ </span>
   <span class="font10">SpO </span>
   <span class="font10">TableÂ </span>
   <span class="font10">This </span>
   <span class="font10">Treatment </span>
   <span class="font10">WHO </span>
   <span class="font10">about </span>
   <span class="font10">adaptive, </span>
   <span class="font10">admission </span>
   <span class="font10">against </span>
   <span class="font10">agent </span>
   <span class="font10">analyses </span>
   <span class="font10">and/or </span>
   <span class="font10">any </span>
   <span class="font10">appears </span>
   <span class="font10">approach </span>
   <span class="font10">arbidol </span>
   <span class="font10">because </span>
   <span class="font10">bold </span>
   <span class="font10">candidate </span>
   <span class="font10">centre </span>
   <span class="font10">courier; </span>
   <span class="font10">disease. </span>
   <span class="font10">drugs </span>
   <span class="font10">em; </span>
   <span class="font10">groups </span>
   <span class="font10">identified </span>
   <span class="font10">improvements </span>
   <span class="font10">kinase </span>
   <span class="font10">levels </span>
   <span class="font10">median </span>
   <span class="font10">mild </span>
   <span class="font10">moderate </span>
   <span class="font10">observational </span>
   <span class="font10">observed </span>
   <span class="font10">outcome </span>
   <span class="font10">patients, </span>
   <span class="font10">placebo </span>
   <span class="font10">provides </span>
   <span class="font10">pt;} </span>
   <span class="font10">publications </span>
   <span class="font10">radiation </span>
   <span class="font10">rate </span>
   <span class="font10">rates </span>
   <span class="font10">received </span>
   <span class="font10">recovery </span>
   <span class="font10">report </span>
   <span class="font10">resource </span>
   <span class="font10">ruxolitinib </span>
   <span class="font10">series: </span>
   <span class="font10">shorter </span>
   <span class="font10">some </span>
   <span class="font10">status </span>
   <span class="font10">storm </span>
   <span class="font10">supporting </span>
   <span class="font10">treatment. </span>
   <span class="font10">unit </span>
   <span class="font10">without </span>
   <span class="font10">â‰¤% </span>
  </p>
 </body>
</html>
